Quince Stock Price, News & Analysis

Quince Therapeutics (Nasdaq: QNCX) announced publication in Frontiers in Drug Delivery summarizing eight early-stage clinical trials of its lead asset eDSP (dexamethasone sodium phosphate encapsulated in autologous red blood cells) in pulmonary and inflammatory bowel disorders.

Key findings: eDSP was dosed every two weeks or monthly across ages 5–83, produced improved FEV1 and fewer infections in cystic fibrosis, improved COPD symptoms with lower steroid exposure, enabled corticosteroid withdrawal in 60%–78% of IBD patients, and showed DSP levels persisting up to 28 days post-infusion; mean infusion dose did not exceed 10 mg.

Quince Therapeutics (Nasdaq: QNCX) announced senior management will participate in three investor events in December 2025: a Piper Sandler fireside chat on Dec 3, 2025 at 10:30 AM ET, a panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, and a virtual Lunch with LifeSci fireside chat on Dec 16, 2025 at 1:00 PM ET. Presenters include Dirk Thye, M.D. (CEO & CMO), Charles Ryan, J.D., Ph.D. (President), and Brendan Hannah (COO & CBO). The Piper Sandler and LifeSci sessions will be webcast with archives available, and the Oppenheimer panel highlights near-term catalysts as Quince advances toward pivotal Phase 3 NEAT topline results expected in Q1 2026.

Quince Therapeutics (Nasdaq: QNCX) reported Q3 2025 results and a business update. The company completed enrollment in its pivotal Phase 3 NEAT trial with 105 total participants (83 in the six-to-nine year-old primary analysis group) and expects topline results in Q1 2026. The trial operates under an FDA SPA, has FDA Fast Track designation, and an iDSMB recommended continuation without modification; 100% of participants elected the open-label extension.

Q3 cash, cash equivalents, and short-term investments totaled $26.3M, with a cash runway expected into Q2 2026 (potential extension into H2 2026 if warrants are exercised). Q3 net loss was $13.3M (loss per share $0.25).

Quince Therapeutics (Nasdaq: QNCX) reported a positive pre-planned safety review by an independent data and safety monitoring board (iDSMB) for its pivotal Phase 3 NEAT trial of encapsulated dexamethasone sodium phosphate (eDSP) in patients with Ataxia-Telangiectasia (A-T).

The iDSMB found no safety concerns and recommended the study continue without modifications. The international, multicenter, randomized, double-blind, placebo-controlled trial enrolls two cohorts (1:1 randomization) with six infusions given every 21–30 days. The primary endpoint is change from baseline to last efficacy visit on the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS). Quince expects to report topline results in Q1 2026.

Quince Therapeutics (Nasdaq: QNCX) presented a poster on patient‑reported walking capacity in children with Ataxia‑Telangiectasia (A‑T) at the 54th Child Neurology Society Annual Meeting on October 9, 2025.

The cross‑sectional natural history analysis used data from 372 children in the Global A‑T Family Data Platform to describe age‑related loss of ambulation. A patient‑reported walking scale was compared with clinician measures ICARS and RmICARS, showing all three scales tracked walking decline similarly. Findings suggest the RmICARS walking components may be suitable for assessing A‑T disease progression and are relevant to the company's Phase 3 NEAT trial of encapsulated dexamethasone sodium phosphate (eDSP, NCT06193200).

Quince Therapeutics (Nasdaq: QNCX) announced the publication of a population pharmacokinetic modeling study for its Phase 3 lead asset, eDSP, in the journal CPT: Pharmacometrics & Systems Pharmacology. The study focused on pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adults.

The research demonstrated that eDSP, which encapsulates dexamethasone sodium phosphate in patients' own red blood cells, maintains sustained plasma concentrations for 20-30 days without drug accumulation. The PK model, developed using data from 24 healthy adults and 109 pediatric A-T patients, confirmed eDSP's sustained release properties and favorable safety profile with minimal corticosteroid-related side effects.

Quince Therapeutics (Nasdaq: QNCX) announced it will host a virtual Investor Day on October 2, 2025, from 10:00 AM to 12:00 PM ET. The event will showcase the company's Autologous Intracellular Drug Encapsulation (AIDE) technology and proprietary eDSP System for chronic corticosteroid delivery.

Key presentations will cover their pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T), with topline results expected in Q1 2026. The company will discuss its regulatory pathway, including Special Protocol Assessment agreement with FDA, orphan drug and Fast Track designations. Additional topics include commercial launch preparations with Option Care Health and potential expansion into other rare diseases like Duchenne muscular dystrophy.

Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focused on rare disease treatments, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's CEO and CMO, Dr. Dirk Thye, will deliver a presentation that will be available on September 5, 2025, at 7:00 a.m. ET.

Investors can access the presentation webcast through Quince's Investor Relations website at ir.quincetx.com, with an archive available after the event.

Quince Therapeutics (Nasdaq: QNCX) announced significant progress in Q2 2025, highlighted by the completion of enrollment in its pivotal Phase 3 NEAT clinical trial for A-T treatment. The trial enrolled 105 participants, with topline results expected in Q1 2026. The company secured financing that brought its cash position to $34.7 million, providing runway through Phase 3 results into Q2 2026.

Key financial results include R&D expenses of $6.6 million, G&A expenses of $3.3 million, and a net loss of $16.1 million ($0.34 per share). Quince entered a strategic partnership with Option Care Health for U.S. commercial launch support and closed a premium-priced private placement led by Nantahala Capital, generating $11.5 million in upfront proceeds with potential additional proceeds of up to $10.4 million from warrants.